CN117959382A - Traditional Chinese medicine composition for treating pulmonary nodules and application thereof - Google Patents
Traditional Chinese medicine composition for treating pulmonary nodules and application thereof Download PDFInfo
- Publication number
- CN117959382A CN117959382A CN202311769348.2A CN202311769348A CN117959382A CN 117959382 A CN117959382 A CN 117959382A CN 202311769348 A CN202311769348 A CN 202311769348A CN 117959382 A CN117959382 A CN 117959382A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- treating pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 37
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 26
- 241000237502 Ostreidae Species 0.000 claims abstract description 26
- 235000020636 oyster Nutrition 0.000 claims abstract description 26
- 210000000582 semen Anatomy 0.000 claims abstract description 22
- 241001547125 Fritillaria thunbergii Species 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 206010056342 Pulmonary mass Diseases 0.000 claims description 28
- 239000002775 capsule Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 35
- 208000026435 phlegm Diseases 0.000 description 35
- 210000004072 lung Anatomy 0.000 description 27
- 206010054107 Nodule Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 24
- 238000011282 treatment Methods 0.000 description 22
- 238000003745 diagnosis Methods 0.000 description 20
- 206010011224 Cough Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 210000000038 chest Anatomy 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 208000000059 Dyspnea Diseases 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 201000008827 tuberculosis Diseases 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000935235 Fritillaria meleagris Species 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 4
- 244000078912 Trichosanthes cucumerina Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000000616 Hemoptysis Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 241000132012 Atractylodes Species 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 235000013717 Houttuynia Nutrition 0.000 description 2
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 240000005856 Lyophyllum decastes Species 0.000 description 2
- 235000013194 Lyophyllum decastes Nutrition 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 240000000377 Tussilago farfara Species 0.000 description 2
- 235000004869 Tussilago farfara Nutrition 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 229960004884 fluconazole Drugs 0.000 description 2
- 239000005337 ground glass Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960003702 moxifloxacin Drugs 0.000 description 2
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000000630 Bronchogenic cyst Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000212941 Glehnia Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 244000116484 Inula helenium Species 0.000 description 1
- 235000002598 Inula helenium Nutrition 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 241000217407 Margaritifera Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 208000030633 Pulmonary arteriovenous malformation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 240000006023 Trichosanthes kirilowii Species 0.000 description 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000011298 ablation treatment Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940124976 antitubercular drug Drugs 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 201000011121 diffuse pulmonary fibrosis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000017762 fibroma of lung Diseases 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000017772 hamartoma of lung Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000001142 lung small cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- -1 navel patch Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- VSRBKQFNFZQRBM-UHFFFAOYSA-N tuaminoheptane Chemical compound CCCCCC(C)N VSRBKQFNFZQRBM-UHFFFAOYSA-N 0.000 description 1
- 229960003986 tuaminoheptane Drugs 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating pulmonary nodules, which is prepared from the following components in parts by weight: 5-10 parts of tangerine pith, 10-30 parts of fritillaria thunbergii, 10-30 parts of semen trichosanthis, 10-30 parts of raw oyster and 5-15 parts of fructus forsythiae. The traditional Chinese medicine composition provided by the invention has the advantages of low cost of raw materials, simple and convenient preparation and convenient use. The traditional Chinese medicine composition is safe and nontoxic, and can be taken for a long time.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating pulmonary nodules and application thereof.
Background
Pulmonary nodules (pulmonary nodule, PN) are a clinically common sign, meaning round-like or irregular lesions with an internal diameter of less than or equal to 3cm (i.e., 30 mm) in the lung, are imaged as shadows of increased density, can be single or multiple, and have clear or unclear boundaries. It is often found by accident that the symptoms of most patients are not obvious during physical examination or diagnosis of other diseases, and symptomatic patients often show symptoms such as dyspnea, chest pain, cough, hemoptysis and the like.
Etiology of lung nodules:
1. Basic etiology (1) malignant lesions ① primary lung cancer: mainly comprises lung adenocarcinoma, lung squamous cell carcinoma, lung large cell carcinoma and lung small cell carcinoma. ② Metastatic malignancy: such as malignant tumor of head and neck, melanoma, colon cancer, etc. (2) Benign lesions ① benign tumor: such as lung hamartoma, lung fibroma, lung lipoma, etc. ② infection: mycobacterium tuberculosis infection, pulmonary fungus (such as candida, aspergillus, mucor) infection, etc. ③ Inflammatory lesions: such as granulomatosis, sarcoidosis, etc. ④ Pulmonary vascular abnormalities: such as pulmonary arteriovenous malformations, pulmonary telangiectasis, etc. ⑤ Congenital diseases of the lung: such as bronchogenic cyst, pulmonary isolation, etc.
2. The high risk factor (1) is smoking or has a history of smoking. (2) the presence of a fungal or bacterial infection of the lung. (3) past malignant tumors or a family history of lung cancer. (4) There is a history of environmental or high risk occupational exposure, such as frequent exposure to asbestos, beryllium, uranium, radon, and the like. (5) Chronic obstructive pulmonary disease and diffuse pulmonary fibrosis are combined.
Typical manifestations of pulmonary nodule symptoms:
1. cough: persistent repetitive cough can occur when a pulmonary nodule affects pulmonary nerves. Lung nodules caused by infection are often accompanied by purulent sputum.
2. Chest pain: when a tumor or tuberculosis focus affects the pleura or chest wall, chest pain may develop, which may be exacerbated with respiratory movement and cough.
3. Dyspnea: if the nodule is continuously enlarged, chest distress, short breath, wheezing, dyspnea and other symptoms can occur when the bronchus is pressed.
4. Hemoptysis: when a nodule reaches a pulmonary vessel, a patient may develop hemoptysis symptoms.
5. Systemic manifestations: for lung nodules caused by malignant tumor or tuberculosis infection, nonspecific manifestations such as debilitation, low fever, weight loss, night sweat (night sleep sweating, sweat after waking and stopping) and the like can appear. High fever can occur if the tuberculosis focus spreads sharply.
Treatment of pulmonary nodules: it is expected that the treating physician will administer a personalized treatment regimen based on the cause of the pulmonary nodules. If a lung nodule is diagnosed as benign or malignant, surgical excision may be considered; anti-tuberculosis and antifungal treatments are respectively applied to the patients caused by the mycobacterium tuberculosis infection and the fungal infection. If the lung nodule is not qualitative, but the judgment can be made by an observer, a doctor can make a proper follow-up plan for the patient according to the malignancy probability of the nodule.
Drug treatment of lung nodules:
1. Antitubercular drugs are mainly used for pulmonary nodules caused by pulmonary tuberculosis. The common medicines are isoniazid, rifampicin and the like, which can kill tubercle bacillus and achieve the purpose of controlling illness state.
2. The common antibiotics include ofloxacin, norfloxacin, moxifloxacin, erythromycin, etc. Mainly aims at patients with infection symptoms and can prevent secondary infection.
3. The antifungal agent is mainly used for patients with fungal infection, and common medicines include itraconazole, fluconazole, terbinafine hydrochloride and the like. Related medicines such as isoniazid, rifampin, ofloxacin, norfloxacin, moxifloxacin, erythromycin, itraconazole, fluconazole and terbinafine hydrochloride.
Surgical treatment of lung nodules:
1. Surgical mode
(1) Television assisted thoracoscopic surgery (vat): the doctor makes a small incision in the patient's chest and inserts a tube with a camera and light source for surgery. Has the characteristics of wide visual field, small wound, light pain and quick postoperative rehabilitation. Meanwhile, more mediastinal lymph nodes can be cleaned, the incidence rate of lymph node residue is reduced, and the method is a main operation mode at present.
(2) Thoracotomy: for deeper lung nodules, open chest surgery may be required.
2. Surgical resection scope physicians may administer sub-lobe or lobe resections, wedge resections, lung segments or sub-lobe segment resections, regional lymph node cleaning, etc., depending on the size, nature, etc. of the nodule. Other treatments for highly malignant probability lung nodules that cannot tolerate surgery, ablation treatments may be considered after PET evaluation.
Lung nodules are often free of special symptoms at early stages, often found during physical examination of chest CT examinations, and their scientific management is important, focusing on distinguishing benign from malignant nodules, avoiding excessive invasive examination and treatment of benign nodules, while early detection of malignant nodules gives intervention, maintains or reduces benign lung nodule size to some extent, and improves patient quality of life. Western medicine often takes follow-up visit to lung nodules which do not reach the operation indication as the main part, treatment measures are limited, patients often cannot be effectively treated, and mental stress is high, so that malignant circulation is formed. At this time, the Chinese medicine can fully exert advantages, and can treat the pulmonary nodules in multiple targets, multiple ways and multiple directions.
The traditional Chinese medicine considers that the lung nodule is a pathogenic factor and is mainly formed by mutually blooding phlegm, blood stasis and toxin, and the nodule is enlarged when the nodule is developed to be combined with infection and shows some syndrome characteristics, and can be characterized by the syndrome of qi stagnation and phlegm obstruction, the syndrome of cold phlegm stagnation, the syndrome of damp-heat and phlegm stasis, the syndrome of yang deficiency and internal heat and the like of the traditional Chinese medicine. The traditional Chinese medicine has rich experience, rich treatment method and higher curative effect, combines the disease differentiation and syndrome differentiation of the modern traditional Chinese medicine, explores a plurality of new treatment schemes and prescription drugs, and clinically shows unique advantages.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating pulmonary nodules.
The invention also aims at providing an application of the traditional Chinese medicine composition in preparing medicines for treating pulmonary nodules.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
The invention provides a traditional Chinese medicine composition for treating pulmonary nodules, which is prepared from the following components in parts by weight: 5-10 parts of tangerine pith, 10-30 parts of fritillaria thunbergii, 10-30 parts of semen trichosanthis, 10-30 parts of raw oyster and 5-15 parts of fructus forsythiae.
The traditional Chinese medicine composition for treating lung nodules is prepared from the following components in parts by weight: 8 parts of tangerine pith, 25 parts of fritillaria thunbergii, 15 parts of semen trichosanthis, 15 parts of raw oyster and 10 parts of weeping forsythiae capsule.
The traditional Chinese medicine composition for treating lung nodules is prepared from the following components in parts by weight: 10 parts of tangerine pith, 30 parts of fritillaria thunbergii, 30 parts of semen trichosanthis, 20 parts of raw oyster and 9 parts of weeping forsythiae capsule.
The traditional Chinese medicine composition for treating lung nodules is prepared from the following components in parts by weight: 6 parts of tangerine pith, 20 parts of fritillaria thunbergii, 10 parts of semen trichosanthis, 10 parts of raw oyster and 7 parts of fructus forsythiae.
The traditional Chinese medicine composition for treating lung nodules is prepared from the following components in parts by weight: 7 parts of tangerine pith, 10 parts of fritillaria thunbergii, 20 parts of semen trichosanthis, 15 parts of raw oyster and 8 parts of fructus forsythiae.
The traditional Chinese medicine composition for treating lung nodules is prepared from the following components in parts by weight: 9 parts of tangerine pith, 15 parts of fritillaria thunbergii, 15 parts of semen trichosanthis, 30 parts of raw oyster and 12 parts of fructus forsythiae.
In a second aspect, the invention provides application of the traditional Chinese medicine composition in preparation of medicines for treating pulmonary nodules.
In a third aspect of the present invention, a Chinese medicinal preparation is provided, which is prepared from the above Chinese medicinal composition.
The Chinese medicinal preparation is in the form of decoction, tablet, mixture, oral liquid, granule, pill, capsule, navel patch, and suppository.
The invention takes tangerine pith and fritillary bulb as monarch drugs to play the role of regulating qi, resolving stagnation, resolving phlegm and resolving masses. Semen Trichosanthis is used as ministerial drug for clearing lung-heat and eliminating phlegm, oyster is used for suppressing yang and nourishing yin, descending the evil in chest, fructus forsythiae is used as conductant drug for guiding the drug into the channel and directly reaching the disease site, and is used for clearing lung-heat and eliminating phlegm, and detumescence and resolving masses together. Promoting qi circulation, resolving phlegm, resolving masses and strengthening body resistance, and can achieve the effects of eliminating pathogenic factors, strengthening body resistance and smoothing yin and yang.
The traditional Chinese medicine raw material medicine has the following main functions of taste, meridian tropism:
The invention takes the symptoms of upper energizer, obstruction of collaterals and qi obstruction, phlegm and qi obstruction, and heat transformation caused by depression as the symptoms, and treats the symptoms of regulating qi movement, dredging collaterals and resolving hard mass, clearing lung and moistening lung.
Orange collaterals are neutral in nature, sweet and bitter in taste, and enter lung and spleen meridians. The tangerine pith has the effects of relieving the nature of the medicine, regulating the flow of qi, strengthening the spleen, removing food retention and eliminating stagnation, and is especially good at dredging the channels and collaterals and eliminating phlegm; zhejiang fritillary bulb, bitter and cold, enters lung and heart meridians. Has effects of clearing heat, eliminating phlegm, descending qi, relieving cough, resolving hard mass, and detumescence, and is good at clearing lung heat from exterior and interior, resolving phlegm. The compendium of the eye to pick up the effect indicates: the tangerine pith can be used for dredging channels and collaterals, relieving qi stagnation and pulse distention, dispelling phlegm and promoting blood circulation. In Ben Cao gang mu Shi (compendium of materia Medica and its excessive body), zhe Bei mu can detoxify and promote phlegm, open and ventilate lung qi, so it is indicated for wind-fire with phlegm. The two are main medicines of the composition, and play roles of dredging collaterals, dispersing phlegm and clearing exterior and interior.
Fructus Trichosanthis is has sweet and bitter taste and cold nature, and has effects of clearing heat and eliminating phlegm, relieving chest stuffiness and resolving hard mass, moistening dryness and lubricating intestines when growing at Shen Yue, heptin and unitary month, unitary containing and unitary month corresponding to lung, stomach and large intestine channels. For upper heat in the lung, middle energizer is smoothened, lower intestine is smoothened, and qi movement of the whole body is smoothened; oyster is salty and slightly cold, enters liver and kidney meridians, and causes qi of human body to converge and descend. Has the effects of astringing yin, softening hardness and resolving hard mass, and can treat scrofula. Oyster is better at breaking and resolving phlegm. "Jingyue holly book": gua Lou ren is thick in flavor and is moist and descending in nature. Can reduce excessive heat phlegm and saliva, relieve depression, block qi, quench thirst, relieve distention and asthma, moisten lung and relieve cough. In Changsha Yaojie Jie (Changsha drug solution): all phlegm-blood symptoms, gall, scrofula and the like are treated. It can be seen that the two herbs are combined to have more special effect.
Fructus forsythiae is a key herb for treating heat in upper jiao, especially for resolving toxin and carbuncle and resolving hard mass, and is bitter in flavor, and is effective in clearing lung heat, resolving phlegm, relieving swelling and resolving hard mass. Overall, fructus forsythiae and fritillariae thunbergii have the effect of dispersing and smoothing, and cooperate with the subsidence of semen trichosanthis and raw oyster to regulate the qi movement of a human body, so that qi flow is along with phlegm and the raw oyster and tangerine pith walk through viscera and channels as special medicines, and the functions of promoting qi circulation, reducing phlegm and resolving masses are combined, and both symptoms and root causes are treated, so that the effects of eliminating pathogenic factors, strengthening body resistance and smoothing yin and yang are achieved.
By adopting the technical scheme, the invention has the following advantages and beneficial effects:
the traditional Chinese medicine composition provided by the invention has the advantages of low cost of raw materials, simple and convenient preparation and convenient use. The traditional Chinese medicine composition is safe and nontoxic, and can be taken for a long time.
Detailed Description
In order to more clearly illustrate the present invention, the present invention will be further described with reference to preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and that this invention is not limited to the details given herein.
Example 1
A Chinese medicinal composition for treating pulmonary nodule:
mixing tangerine pith 8g, fritillaria thunbergii 25g, snakegourd fruit 15g, raw oyster 15g and weeping forsythiae capsule 10 g; reflux-extracting with water for 3 times (1000 ml,1 hr; 1000ml,1 hr), mixing extractive solutions, concentrating, oven drying, and pulverizing.
Example 2
A Chinese medicinal composition for treating pulmonary nodule:
mixing and grinding 10g of tangerine pith, 30g of fritillaria thunbergii, 30g of semen trichosanthis, 20g of raw oyster and 9g of fructus forsythiae; reflux-extracting with water for 3 times (1000 ml,1 hr; 1000ml,1 hr), mixing extractive solutions, and concentrating to obtain extract; adding proper pharmaceutical adjuvants (white sugar, mel, benzoic acid or ethyl hydroxy benzoate, etc.), and making into pill, mixture, oral liquid or syrup.
Example 3
A Chinese medicinal composition for treating pulmonary nodule:
Mixing 6g of tangerine pith, 20g of fritillaria thunbergii, 10g of semen trichosanthis, 10g of raw oyster and 7g of fructus forsythiae; reflux-extracting with water for 3 times (1000 ml,1 hr; 1000ml,1 hr), mixing extractive solutions, concentrating to obtain extract, drying, pulverizing, and making into granule.
Example 4
Mixing pericarpium Citri Tangerinae 7g, bulbus Fritillariae Thunbergii 10g, semen Trichosanthis 20g, concha Ostreae 15g, and fructus forsythiae 8 g; reflux-extracting with water for 3 times (1000 ml,1 hr; 1000ml,1 hr), mixing extractive solutions, concentrating to obtain extract, drying, pulverizing into granule, adding adjuvant, and making into tablet or capsule.
Example 5
Mixing 9g of tangerine pith, 15g of fritillaria thunbergii, 15g of semen trichosanthis, 30g of raw oyster and 12g of fructus forsythiae; reflux-extracting with water for 3 times (1000 ml,1 hr; 1000ml,1 hr), mixing the extractive solutions, and concentrating to obtain decoction.
Example 6
1. Case selection and grouping
(1) Case selection: refer to the "Chinese lung nodule classification, diagnosis and treatment guide (2016 edition)" formulated by the Chinese lung nodule diagnosis and treatment expert group 2016 in the "Chinese expert consensus for diagnosis and treatment of lung nodule (2018 edition)".
① Quantity: individual lesions are isolated, and 2 or more lesions are defined as multiple lesions.
② Density: the solid nodules, the ground glass nodules, and the partially solid nodules are classified into 3 categories based on the density and the degree of mixing.
③ Degree of risk: the solid nodule refers to the result of a Mayo malignancy probability prediction formula, and the lung cancer risk factors are divided into <5% (low risk), 5% -65% (medium risk) and >65% (high risk); the partial solid nodules are bounded by 8mm, >8mm (high risk), <8mm (medium risk); the pure ground glass nodules were bounded by 5mm, >5mm (medium risk), <5mm (low risk). Multiple nodules were ranked by the most dangerous nodules.
(2) Case grouping: the treatment groups and the control groups were randomized according to a random table.
① Treatment group (administration of the formulation prepared in example 5 of the invention + follow-up): 105 cases.
② Control group (follow-up only): 105 cases.
The two groups of patients were comparable with no significant differences in age, sex, course of disease and severity of disease (P > 0.05).
2. Method of observation and treatment
① The observation method comprises the following steps: the morphology of lung CT lung nodules was observed before and after treatment of group 2.
② The treatment method comprises the following steps: 150ml of the medicine is taken twice a day, each time in the morning and evening, and 3 months is a treatment course.
3. Standard of efficacy: reference is made to the guidelines of clinical research on new Chinese medicine.
(1) Clinical recovery: the lung nodules disappeared;
(2) The effect is shown: lung nodules were reduced by more than 60%;
(3) The method is effective: the lung nodule is reduced by 30 to 59 percent;
(4) Invalidation: pulmonary nodules do not change or turn into high risk nodules;
The total effective rate is the sum of healing, obvious effect and effective rate.
4. Therapeutic results and analysis
① Treatment group 105 cases, effects are shown in table 1:
TABLE 1
30 Cases are clinically cured, 12 cases are obvious, 32 cases are effective, 31 cases are ineffective, and the total effective rate is 70.50%.
② The effect of 105 cases of control group is shown in Table 2:
TABLE 2
6 Cases of clinical recovery, 7 cases of obvious effect, 15 cases of effective and 77 cases of ineffective, and the total effective rate is 26.67%.
Compared with the control group, the total effective rate of the patients in the treatment group is obviously higher than that of the patients in the control group, the difference is obvious, and the statistical significance is achieved (P < 0.05).
Example 7
The patient had a yellow spot, and had a first visit in year 2021, month 5 and 25, with a 41 year old male. Patients on day 19, 1, 2021 were examined in local hospitals and chest CT: the basal segment nodule behind the inferior lobe of the right lung is approximately 6mm in diameter and is clearly defined. Tumor markers such as carcinoembryonic antigen are not abnormal, related treatment is not carried out temporarily, and the patient suffers from stay overnight from insomnia and even anxiety after finding out the nodule.
The diagnosis is as follows: sleep, dry mouth, anorexia, dry stool, urine, red tongue, thin and yellow coating, dark red lip surface, red eyes, and deep and thready pulse.
Western diagnosis: insomnia, lung nodules. Diagnosis of traditional Chinese medicine: insomnia (pattern of hyperactivity of fire due to yin deficiency).
Prescription: 15g of fritillary bulb, 9g of tangerine pith, 15g of snakegourd fruit, 15g of peach seed and 15g of raw oyster; fructus forsythiae 12g, radix glehniae 15g, radix ophiopogonis 15g, spina date seed 15g, poria with hostwood 15g, mother-of-pearl 30g, fried chicken's gizzard-skin 12g and fried liquorice 9g. A total of 28 doses, 1 dose/day, 150ml each time, are decocted with water.
Two diagnoses: re-diagnosis in 2021 at 6 and 23 days, patients complain of sleep gradually, no dry mouth and inconvenient adjustment, but slightly sour after eating, go to Zhu Fu Shen and Zhenzhu Ping, add calcined flute 30g and take for 2 months.
Three diagnoses: the symptoms of complaints are healed in the 8 th year of 2021 and 18 th year, the upper part is calcined, the flute is calcined, the spine date seed, the glehnia root and the dwarf lilyturf tuber are removed, the chest CT is checked after 3 months of taking, the telephone is followed in the 11 th month of 2021, and the two lungs are not obviously abnormal when the chest CT is checked in the local hospital in the 11 th month of 2021.
The preparation method comprises the following steps: the patient has plain character, is prone to have a frequent check, has serious anxiety in the recent times, has poor qi activity, and has the effects of fluid resistance, phlegm generation, blood stagnation, stasis and phlegm stasis; yin-fluid deficiency failing to nourish the body and deficient heat is generated internally. Considering the basic pathogenesis in conjunction with tongue pulse is: phlegm and blood stasis are mutually combined, and fire is excessive due to yin deficiency. The recipe is effective in activating qi-flowing, resolving phlegm, resolving stagnation, nourishing yin and tranquilizing mind. Modified by taking the traditional Chinese medicine composition as the basis for temporary symptoms. In the formula, fritillary bulb, tangerine pith, and tangerine pith have the functions of regulating qi, resolving stagnation, resolving phlegm and resolving masses; radix glehniae, radix ophiopogonis, capable of nourishing yin, moisturizing lung, benefiting stomach and promoting fluid production; semen Ziziphi Spinosae, poria and Concha Margaritifera can calm heart and tranquilize mind; semen Persicae and semen Trichosanthis have effects of loosening bowel to relieve constipation, removing blood stasis and resolving hard mass; oyster can be used for resolving masses and eliminating mass, and green fructus forsythiae can be introduced into the channels to directly reach the disease sites; the whole formula plays the roles of eliminating symptoms, resolving hard mass and harmonizing yin and yang together. The patients with the second diagnosis all have reduced symptoms, but are slightly sour after eating, so Zhu Fu Shen and Zhu mu are removed, and 30g of calcined concha arcae are added, so that the effects of inhibiting acid, eliminating phlegm, softening hardness and resolving hard mass are enhanced. The three patients with all symptoms are cured, the bellyband is pathogenic, the disease condition is lingering, frequent review is not suitable, the special traditional Chinese medicine composition of the invention is taken for three months for observing the curative effect, and then the pulmonary nodule disappears.
Example 8
The patient had a certain, male, 61 years old, 2021, 4 months, 13 days first visit. The patient is going to local hospital for diagnosis and treatment for cough of 1 month or more due to cold, 2021, 4 months and 9 days, and chest CT examination shows: the upper She Duofa nodules of the left lung, approximately 8mm. Tumor markers were not abnormal. Related treatments were not performed. The diagnosis is as follows: cough, expectoration, debilitation, shortness of breath, loose stool, urine, pale tongue with white and thin coating, pale lips, pale complexion and thready pulse.
Western diagnosis: cough, lung nodules. Diagnosis of traditional Chinese medicine: cough (qi deficiency of lung and spleen).
Prescription: 15g of fritillary bulb, 9g of tangerine pith, 15g of snakegourd fruit, 15g of peach seed and 15g of raw oyster; 12g of fructus forsythiae; 15g of astragalus; 15g of raw white atractylodes rhizome; 30g of radix pseudostellariae; 30g of cordate houttuynia; 15g of coltsfoot flower; 9g of costustoot; 12g of fried chicken's gizzard-membrane; radix Glycyrrhizae Preparata 9g. A total of 28 doses, 1 dose/day, 150ml each time, are decocted with water.
Two diagnoses: re-diagnosis in 2021, 5 and 11 days, cough, expectoration, hypodynamia, shortness of breath and constipation. Herba Houttuyniae, flos Farfarae and radix aucklandiae are removed from the upper part, and the mixture is taken for 2 months.
Three diagnoses: re-diagnosis is performed in 7 th year and 6 th year of 2021, complaints are all healed, astragalus root, raw atractylodes macrocephala koidz and radix pseudostellariae are removed from the upper part, and chest CT is re-checked after taking three months.
Four diagnostic methods: re-examination at 28 days of 10 months of 2021, re-examination at 27 days of 10 months of 2021 chest distress CT shows: the upper left lung is a tiny nodule, about 3mm, smaller than 2021-4-9 tablets. Patients have no special discomfort, stop taking the traditional Chinese medicine, and review chest CT every half year with the help of diagnosis.
The preparation method comprises the following steps: the patients are diagnosed with cough after one month, the symptoms are as follows: phlegm, weakness, shortness of breath, loose stool, pale and fat tongue with tooth marks, thin and white coating and thin pulse, which are considered as the symptoms of qi deficiency of lung and spleen, qi deficiency of other viscera, weak promotion of qi deficiency, unsmooth blood circulation and stasis; spleen deficiency causes insufficient transportation and transformation, and phlegm-dampness is self-generated. The pathogenesis of the disease is as follows: qi deficiency of the lung and spleen, and blood stasis due to phlegm coagulation. The traditional Chinese medicine composition disclosed by the invention is materialized and cut for tonifying qi and resolving phlegm, and relieving cough and removing blood stasis, radix pseudostellariae, astragalus and raw bighead atractylodes rhizome in the formula have the effects of tonifying qi and strengthening spleen, promoting the production of body fluid and moistening lung, and radix aucklandiae has the effects of warming middle-jiao and harmonizing stomach and relieving diarrhea with astringents, and herba houttuyniae, flos farfarae and radix glycyrrhizae preparata are added to increase the effects of relieving cough and resolving phlegm, so that radix glycyrrhizae preparata has the effects of harmonizing various medicines. Cough and expectoration of patients with secondary diagnosis are healed, and the cough and expectoration of patients with secondary diagnosis still have weak and shortness of breath, so the cordate houttuynia, the coltsfoot flower and the elecampane are removed, and the traditional Chinese medicine composition is taken for 2 months. Three patients have no symptoms, and the breast CT is rechecked to reduce the nodule to 3mm after taking the traditional Chinese medicine composition of the invention for 3 months. The prescription for clinical symptoms is not more than ten digits, but the prescription is seemingly concise and practical, and has the advantages of simplified and high effect when the prescription is used for treating the symptom.
Example 9
The patient is a female, 54 years old, and Han nationality. Breast CT at outer hospital, 5 months, 18 days 2021: the upper lobe solid nodules (lamellar, im30,4 mm) of the left lung were followed; the medial lobe of the right lung has a few fibroproliferative lesions. Tumor markers are not abnormal, and the diagnosis is from 6 th month 5 th year 2021 to the clinic, and the diagnosis is carved: the symptoms of debilitation, cough, phlegm, chest distress, and short breath are not obvious, the symptoms of anorexia, insomnia, constipation, pale red tongue with thin and white coating, and deep and thready pulse are not obvious.
Prescription: 9g of tangerine pith, 15g of fritillaria thunbergii, 15g of snakegourd fruit, 30g of raw oyster and 12g of weeping forsythia. The medicines are decocted for 1 dose/day, 150ml each time, and the medicines are orally taken in the morning and evening.
Chest CT was reviewed at the outer hospital at 12 months 3 of 2021: no obvious abnormalities were seen.
The foregoing description is only illustrative of the preferred embodiment of the present invention, and is not to be construed as limiting the invention, but is to be construed as limiting the invention to any and all simple modifications, equivalent variations and adaptations of the embodiments described above, which are within the scope of the invention, may be made by those skilled in the art without departing from the scope of the invention.
Claims (9)
1. The traditional Chinese medicine composition for treating lung nodules is characterized by being prepared from the following components in parts by weight: 5-10 parts of tangerine pith, 10-30 parts of fritillaria thunbergii, 10-30 parts of semen trichosanthis, 10-30 parts of raw oyster and 5-15 parts of fructus forsythiae.
2. The traditional Chinese medicine composition for treating pulmonary nodules according to claim 1, wherein the traditional Chinese medicine composition for treating pulmonary nodules is prepared from the following components in parts by weight: 8 parts of tangerine pith, 25 parts of fritillaria thunbergii, 15 parts of semen trichosanthis, 15 parts of raw oyster and 10 parts of weeping forsythiae capsule.
3. The traditional Chinese medicine composition for treating pulmonary nodules according to claim 1, wherein the traditional Chinese medicine composition for treating pulmonary nodules is prepared from the following components in parts by weight: 10 parts of tangerine pith, 30 parts of fritillaria thunbergii, 30 parts of semen trichosanthis, 20 parts of raw oyster and 9 parts of weeping forsythiae capsule.
4. The traditional Chinese medicine composition for treating pulmonary nodules according to claim 1, wherein the traditional Chinese medicine composition for treating pulmonary nodules is prepared from the following components in parts by weight: 6 parts of tangerine pith, 20 parts of fritillaria thunbergii, 10 parts of semen trichosanthis, 10 parts of raw oyster and 7 parts of fructus forsythiae.
5. The traditional Chinese medicine composition for treating pulmonary nodules according to claim 1, wherein the traditional Chinese medicine composition for treating pulmonary nodules is prepared from the following components in parts by weight: 7 parts of tangerine pith, 10 parts of fritillaria thunbergii, 20 parts of semen trichosanthis, 15 parts of raw oyster and 8 parts of fructus forsythiae.
6. The traditional Chinese medicine composition for treating pulmonary nodules according to claim 1, wherein the traditional Chinese medicine composition for treating pulmonary nodules is prepared from the following components in parts by weight: 9 parts of tangerine pith, 15 parts of fritillaria thunbergii, 15 parts of semen trichosanthis, 30 parts of raw oyster and 12 parts of fructus forsythiae.
7. Use of a traditional Chinese medicine composition according to any one of claims 1 to 6 for preparing a medicament for treating pulmonary nodules.
8. A Chinese medicinal preparation prepared from the Chinese medicinal composition according to any one of claims 1 to 6.
9. The traditional Chinese medicine preparation according to claim 8, wherein the dosage form of the traditional Chinese medicine preparation is selected from decoction, tablets, mixture, oral liquid, granules, pills, capsules, navel patches and suppositories.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311769348.2A CN117959382A (en) | 2023-12-21 | 2023-12-21 | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311769348.2A CN117959382A (en) | 2023-12-21 | 2023-12-21 | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117959382A true CN117959382A (en) | 2024-05-03 |
Family
ID=90865324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311769348.2A Pending CN117959382A (en) | 2023-12-21 | 2023-12-21 | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117959382A (en) |
-
2023
- 2023-12-21 CN CN202311769348.2A patent/CN117959382A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114042124B (en) | Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof | |
CN115252748B (en) | Pharmaceutical composition for treating pulmonary nodules and preparation and application thereof | |
CN113599481B (en) | Traditional Chinese medicine composition for treating thyroid diseases and preparation method and application thereof | |
CN110742990B (en) | Traditional Chinese medicine composition for treating non-alcoholic simple fatty liver, preparation and application | |
CN104398806A (en) | Traditional Chinese medicinal preparation for lung cancer postoperative care, and preparation method thereof | |
CN114788858B (en) | Traditional Chinese medicine pill for treating nodules as well as preparation method and application thereof | |
CN103585449B (en) | For treating migrainous Chinese medicine composition | |
CN117959382A (en) | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof | |
CN109865050B (en) | Traditional Chinese medicine composition for inhibiting liver cancer and application thereof | |
CN103877397B (en) | A kind of medicine of radiotherapy injury of lung and preparation method | |
CN103623283B (en) | A kind of Chinese medicine for the treatment of phlegm-damp stagnation type gastric cancer and preparation method thereof | |
CN117244015B (en) | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof | |
CN115317583B (en) | Traditional Chinese medicine composition for gastric cancer postoperative and application thereof | |
CN116617299B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and application thereof | |
CN103520550A (en) | Traditional Chinese medicine for treating external cold internal rheum type chronic bronchitis and preparation method thereof | |
CN113144103B (en) | Traditional Chinese medicine composition for clearing throat and application thereof | |
AU2021103888A4 (en) | Herbal composition for the treatment of prostate cancer and its preparation method and application | |
CN107412547B (en) | Traditional Chinese medicine composition for treating lung cancer and application thereof | |
CN105434533A (en) | Traditional Chinese medicine composition for treating liver cancer | |
CN106138686A (en) | Traditional Chinese medicine preparation for treating early-stage goiter | |
CN115569177A (en) | Traditional Chinese medicine composition for treating plasma cell mastitis and preparation method and application thereof | |
CN104147477A (en) | Chinese medicinal preparation for resisting tumor | |
CN104524312A (en) | Traditional Chinese medicine composition for treating thyroid adenoma caused by phlegm stagnation and blood stasis and preparation method of traditional Chinese medicine composition | |
CN118512562A (en) | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof | |
CN118436748A (en) | Traditional Chinese medicine preparation and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |